| Document and Entity Information | 6 Months Ended |
| Jun. 30, 2018 | |
| Document And Entity Information | |
| Entity Registrant Name | BioLineRx Ltd. |
| Entity Central Index Key | 1,498,403 |
| Document Type | 6-K |
| Document Period End Date | Jun. 30, 2018 |
| Amendment Flag | false |
| Current Fiscal Year End Date | --12-31 |
| Entity Filer Category | Non-accelerated Filer |
| Document Fiscal Period Focus | Q2 |
| Document Fiscal Year Focus | 2,018 |
| CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION (UNAUDITED) - USD ($) $ in Thousands | Jun. 30, 2018 | Dec. 31, 2017 |
| CURRENT ASSETS | ||
| Cash and cash equivalents | $ 5,789 | $ 5,110 |
| Short-term bank deposits | 35,339 | 44,373 |
| Prepaid expenses | 1,231 | 307 |
| Other receivables | 438 | 586 |
| Total current assets | 42,797 | 50,376 |
| NON-CURRENT ASSETS | ||
| Long-term prepaid expenses | 63 | 61 |
| Long-term investment | 1,000 | |
| Property and equipment, net | 2,318 | 2,505 |
| Intangible assets, net | 7,035 | 7,023 |
| Total non-current assets | 9,416 | 10,589 |
| Total assets | 52,213 | 60,965 |
| CURRENT LIABILITIES | ||
| Current maturities of long-term bank loan | 93 | 93 |
| Accounts payable and accruals: | ||
| Trade | 4,128 | 5,516 |
| Other | 1,117 | 1,113 |
| Total current liabilities | 5,338 | 6,722 |
| NON-CURRENT LIABILITIES | ||
| Long-term bank loan, net of current maturities | 109 | 157 |
| Warrants | 580 | 1,205 |
| Total non-current liabilities | 689 | 1,362 |
| COMMITMENTS AND CONTINGENT LIABILITIES | ||
| Total liabilities | 6,027 | 8,084 |
| EQUITY | ||
| Ordinary shares | 2,920 | 2,836 |
| Share premium | 243,883 | 240,682 |
| Capital reserve | 11,343 | 10,337 |
| Other comprehensive loss | (1,416) | (1,416) |
| Accumulated deficit | (210,544) | (199,558) |
| Total equity | 46,186 | 52,881 |
| Total liabilities and equity | $ 52,213 | $ 60,965 |
| CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
| Jun. 30, 2018 | Jun. 30, 2017 | Jun. 30, 2018 | Jun. 30, 2017 | |
| Profit or loss [abstract] | ||||
| RESEARCH AND DEVELOPMENT EXPENSES | $ (4,484) | $ (4,062) | $ (9,554) | $ (7,652) |
| SALES AND MARKETING EXPENSES | (360) | (288) | (844) | (969) |
| GENERAL AND ADMINISTRATIVE EXPENSES | (883) | (844) | (1,958) | (1,874) |
| OPERATING LOSS | (5,727) | (5,194) | (12,356) | (10,495) |
| NON-OPERATING INCOME (EXPENSES), NET | 663 | (4) | 1,125 | (9) |
| FINANCIAL INCOME | 287 | 304 | 462 | 761 |
| FINANCIAL EXPENSES | (11) | (3) | (217) | (9) |
| NET LOSS AND COMPREHENSIVE LOSS | $ (4,788) | $ (4,897) | $ (10,986) | $ (9,752) |
| LOSS PER ORDINARY SHARE - BASIC AND DILUTED | $ (0.05) | $ (0.05) | $ (0.10) | $ (0.13) |
| WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF LOSS PER ORDINARY SHARE | 106,630,704 | 94,487,470 | 106,524,332 | 76,571,351 |
| CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY (UNAUDITED) - USD ($) $ in Thousands | Ordinary shares [Member] | Share premium [Member] | Other comprehensive loss [Member] | Capital reserve [Member] | Accumulated deficit [Member] | Total |
| BALANCE at Dec. 31, 2016 | $ 1,513 | $ 199,567 | $ (1,416) | $ 10,569 | $ (175,206) | $ 35,027 |
| CHANGES FOR | ||||||
| Issuance of share capital, net | 1,056 | 30,241 | 31,297 | |||
| Employee stock options exercised | 1 | 320 | (321) | |||
| Employee stock options forfeited and expired | 1,240 | (1,240) | ||||
| Share-based compensation | 858 | 858 | ||||
| Comprehensive loss for the period | (9,752) | (9,752) | ||||
| BALANCE at Jun. 30, 2017 | 2,570 | 231,368 | (1,416) | 9,866 | (184,958) | 57,430 |
| BALANCE at Dec. 31, 2017 | 2,836 | 240,682 | (1,416) | 10,337 | (199,558) | 52,881 |
| CHANGES FOR | ||||||
| Issuance of share capital, net | 83 | 2,764 | 2,847 | |||
| Employee stock options exercised | 399 | (399) | ||||
| Employee stock options forfeited and expired | 1 | 38 | (39) | |||
| Share-based compensation | 1,444 | 1,444 | ||||
| Comprehensive loss for the period | (10,986) | (10,986) | ||||
| BALANCE at Jun. 30, 2018 | $ 2,920 | $ 243,883 | $ (1,416) | $ 11,343 | $ (210,544) | $ 46,186 |
| CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS (UNAUDITED) - USD ($) $ in Thousands | 6 Months Ended | |
| Jun. 30, 2018 | Jun. 30, 2017 | |
| CASH FLOWS - OPERATING ACTIVITIES | ||
| Comprehensive loss for the period | $ (10,986) | $ (9,752) |
| Adjustments required to reflect net cash used in operating activities (see appendix below) | (2,054) | 1,746 |
| Net cash used in operating activities | (13,040) | (8,006) |
| CASH FLOWS - INVESTING ACTIVITIES | ||
| Investments in short-term deposits | (15,000) | (36,422) |
| Maturities of short-term deposits | 24,385 | 24,233 |
| Proceeds from realization of long-term investment | 1,500 | |
| Purchase of property and equipment | (76) | (90) |
| Purchase of intangible assets | (37) | (3,721) |
| Net cash provided by (used in) investing activities | 10,772 | (16,000) |
| CASH FLOWS - FINANCING ACTIVITIES | ||
| Issuances of share capital, net | 2,847 | 28,312 |
| Repayments of bank loan | (47) | (47) |
| Net cash provided by financing activities | 2,800 | 28,265 |
| INCREASE IN CASH AND CASH EQUIVALENTS | 532 | 4,259 |
| CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD | 5,110 | 2,469 |
| EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS | 147 | 218 |
| CASH AND CASH EQUIVALENTS - END OF PERIOD | 5,789 | 6,946 |
| Income and expenses not involving cash flows: | ||
| Depreciation and amortization | 288 | 250 |
| Long-term prepaid expenses | (2) | (1) |
| Exchange differences on cash and cash equivalents | (147) | (218) |
| Gain on adjustment of warrants to fair value | (625) | |
| Gain on realization of long-term investment | (500) | |
| Share-based compensation | 1,444 | 858 |
| Interest and exchange rate differences on short-term deposits | (351) | (273) |
| Interest and linkage differences on bank loan | (1) | |
| Total income and expense not involving cash flows | 106 | 616 |
| Changes in operating asset and liability items: | ||
| Increase in prepaid expenses and other receivables | (776) | (623) |
| Increase (decrease) in accounts payable and accruals | (1,384) | 1,753 |
| Total Change in operating asset and liability | (2,160) | 1,130 |
| Total Adjustments required to reflect net cash used in operating acivities | (2,054) | 1,746 |
| Supplementary information on interest received in cash | 377 | 258 |
| Supplementary non-cash investment | $ 2,985 | |
| GENERAL INFORMATION | 6 Months Ended |
| Jun. 30, 2018 | |
| Disclosure of general information [Abstract] | |
| GENERAL INFORMATION | NOTE 1 – GENERAL INFORMATION a. General BioLineRx Ltd. (“BioLineRx”), headquartered in Modi’in, Israel, was incorporated and commenced operations in April 2003. BioLineRx and its subsidiaries (collectively, the “Company”) are engaged in the development of therapeutics, from pre-clinical development to advanced clinical trials, primarily in the fields of oncology and immunology. In February 2007, BioLineRx listed its ordinary shares on the Tel Aviv Stock Exchange (“TASE”) and they have been traded on the TASE since that time. Since July 2011, BioLineRx’s American Depositary Shares (“ADSs”) have also been traded on the NASDAQ Capital Market. In March 2017, the Company acquired Agalimmune Ltd. (“Agalimmune”), a privately-held company incorporated in the United Kingdom, with a focus on the field of immuno-oncology. The Company has been engaged in drug development since its incorporation. Although the Company has generated significant revenues from a number of out-licensing transactions in the past, the Company cannot determine with reasonable certainty when and if it will have sustainable profits. b. Approval of financial statements The condensed consolidated interim financial statements of the Company as of June 30, 2018, and for the three and six months then ended, were approved by the Board of Directors on August 7, 2018, and signed on its behalf by the Chairman of the Board, the Chief Executive Officer and the Chief Financial Officer. |
| BASIS OF PREPARATION | 6 Months Ended |
| Jun. 30, 2018 | |
| Disclosure of basis of preparation [Abstract] | |
| BASIS OF PREPARATION | NOTE 2 – BASIS OF PREPARATION The Company’s condensed consolidated interim financial statements as of June 30, 2018 and for the three and six months then ended (the “interim financial statements”) have been prepared in accordance with International Accounting Standard No. 34, “Interim Financial Reporting” (“IAS 34”). These interim financial statements, which are unaudited, do not include all disclosures necessary for a fair statement of financial position, results of operations, and cash flows in conformity with International Financial Reporting Standards (“IFRS”). The condensed consolidated interim financial statements should be read in conjunction with the Company’s annual financial statements as of December 31, 2017 and for the year then ended and their accompanying notes, which have been prepared in accordance with IFRS. The results of operations for the three and six months ended June 30, 2018 are not necessarily indicative of the results that may be expected for the entire fiscal year or for any other interim period. |
| SIGNIFICANT ACCOUNTING POLICIES | 6 Months Ended |
| Jun. 30, 2018 | |
| Disclosure of significant accounting policies [Abstract] | |
| SIGNIFICANT ACCOUNTING POLICIES | NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES The accounting policies and calculation methods applied in the preparation of these interim financial statements are consistent with those applied in the preparation of the annual financial statements as of December 31, 2017 and for the year then ended, except as follows: (i) IFRS No. 9, “Financial Instruments,” which was effective from January 1, 2018, did not have a material effect on the Company’s financial statements; (ii) IFRS No. 15, “Revenue from Contracts with Customers,” also effective from January 1, 2018, is not relevant to the Company’s financial statements because the Company does not have any revenues; (iii) IFRS No. 16, “Leases,” which is not yet in effect and which the Company has not adopted early, was disclosed in the 2017 annual financial statements. The Company is currently evaluating the potential effect of this new guidance on its consolidated financial statements. |
| ISSUANCES OF SHARE CAPITAL AND WARRANTS | 6 Months Ended |
| Jun. 30, 2018 | |
| Disclosure of issuances of share capital and warrants [Abstract] | |
| ISSUANCES OF SHARE CAPITAL AND WARRANTS | NOTE 4 – ISSUANCES OF SHARE CAPITAL AND WARRANTS a. At-the-market (“ATM”) sales agreement with BTIG In October 2017, the Company entered into an at-the-market (“ATM”) sales agreement with BTIG, LLC (“BTIG”), pursuant to which the Company may, at its sole discretion, offer and sell through BTIG, acting as sales agent, ADSs having an aggregate offering price of up to $30.0 million throughout the period during which the ATM facility remains in effect. The Company will pay BTIG a commission of 3.0% of the gross proceeds from the sale of ADSs under the facility. From the effective date of the agreement through June 30, 2018, 3,880,210 ADSs were sold under the program for total net proceeds of approximately $3.9 million, leaving an available balance under the facility of approximately $26.0 million as of June 30, 2018. b. Direct placement of share capital and warrants to BVF In July 2017, the Company completed a direct placement to BVF Partners L.P., its largest shareholder, for aggregate gross proceeds of $9.6 million. The placement consisted of 8,495,575 ADSs, The warrants issued have been classified as a non-current financial liability due to a net settlement provision. This liability is initially recognized at its fair value on the date the contract is entered into and subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss. The fair value of the warrants is computed using the Black and Scholes option pricing model. The fair value of the warrants upon issuance was computed based on the then current price of an ADS, a risk-free interest rate of 1.66% and an average standard deviation of 57.8%. The fair value of the warrants as of June 30, 2018 was based on the then current price of an ADS, a risk-free interest rate of 2.63% and an average standard deviation of 53.8%. |
| SHAREHOLDERS' EQUITY | 6 Months Ended |
| Jun. 30, 2018 | |
| Disclosure of classes of share capital [abstract] | |
| SHAREHOLDERS' EQUITY | NOTE 5 – SHAREHOLDERS’ EQUITY As of December 31, 2017 and June 30, 2018, share capital is composed of ordinary shares, as follows: Number of ordinary shares December 31, June 30, 2017 2018 Authorized share capital 250,000,000 250,000,000 Issued and paid-up share capital 105,063,437 108,029,516 In USD and NIS December 31, June 30, 2017 2018 Authorized share capital (in NIS) 25,000,000 25,000,000 Issued and paid-up share capital (in NIS) 10,506,344 10,802,952 Issued and paid-up share capital (in USD) 2,836,139 2,919,910 |
| REALIZATION OF INVESTMENT IN JOINT VENTURE (iPharma) | 6 Months Ended |
| Jun. 30, 2018 | |
| Disclosure of selling the holdings in the joint venture - iPharma [Abstract] | |
| REALIZATION OF INVESTMENT IN JOINT VENTURE (iPharma) | NOTE 6 – REALIZATION OF INVESTMENT IN JOINT VENTURE (iPharma) In 2016, the Company established a joint venture with I-Bridge Capital, a Chinese venture capital fund focused on developing innovative therapies in China, with each party contributing initial seed capital to the venture of $1.0 million. The joint venture, named iPharma, focused on the development of innovative clinical and pre-clinical therapeutic candidates to serve the Chinese and global healthcare markets. In April 2018, the Company sold its holdings in the joint venture to I-Bridge Capital for cash consideration of $1.5 million. The gain of $0.5 million is included in non-operating income in the statement of comprehensive loss. |
| SHAREHOLDERS' EQUITY (Tables) | 6 Months Ended |
| Jun. 30, 2018 | |
| Disclosure of classes of share capital [abstract] | |
| Schedule of Share Capital | As of December 31, 2017 and June 30, 2018, share capital is composed of ordinary shares, as follows: Number of ordinary shares December 31, June 30, 2017 2018 Authorized share capital 250,000,000 250,000,000 Issued and paid-up share capital 105,063,437 108,029,516 In USD and NIS December 31, June 30, 2017 2018 Authorized share capital (in NIS) 25,000,000 25,000,000 Issued and paid-up share capital (in NIS) 10,506,344 10,802,952 Issued and paid-up share capital (in USD) 2,836,139 2,919,910 |
| ISSUANCES OF SHARE CAPITAL AND WARRANTS (Details) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 6 Months Ended | ||
| Jul. 31, 2017 | Jun. 30, 2018 | Jun. 30, 2017 | Oct. 31, 2017 | |
| Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
| Net proceeds from transaction | $ 2,847 | $ 28,312 | ||
| BVF Partners L.P. [Member] | ||||
| Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
| Net proceeds from transaction | $ 9,600 | |||
| Net proceeds from transaction after deduction | $ 9,500 | |||
| BTIG, LLC [Member] | ||||
| Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
| Aggregate offering price | $ 30,000 | |||
| Percentage of commission on sales agreement | 3.00% | |||
| Share purchase agreement | 3,880,210 | |||
| Net proceeds from transaction | 3,900 | |||
| Available balance under the facility | $ 26,000 | |||
| ADS [Member] | ||||
| Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
| Risk-free interest rate | 1.66% | 2.63% | ||
| Average standard deviation | 57.80% | 53.80% | ||
| ADS [Member] | BVF Partners L.P. [Member] | ||||
| Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
| Number of shares issued in direct placement | 8,495,575 | |||
| ADS [Member] | BVF Partners L.P. [Member] | Series A warrants [Member] | ||||
| Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
| Warrants purchase to additional ADSs | 2,973,451 | |||
| Exercise price of warrants | $ 2 | |||
| Exercisable period of warrants | four years | |||
| ADS [Member] | BVF Partners L.P. [Member] | Series B warrants [Member] | ||||
| Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
| Warrants purchase to additional ADSs | 2,973,451 | |||
| Exercise price of warrants | $ 4 | |||
| Exercisable period of warrants | four years | |||
| SHAREHOLDERS' EQUITY (Schedule of Share Capital) (Details) ₪ in Thousands, $ in Thousands | Jun. 30, 2018USD ($)shares | Jun. 30, 2018ILS (₪)shares | Dec. 31, 2017USD ($)shares | Dec. 31, 2017ILS (₪)shares |
| Number of Ordinary Shares | ||||
| Authorized share capital | shares | 250,000,000 | 250,000,000 | 250,000,000 | 250,000,000 |
| Issued and paid-up share capital | shares | 108,029,516 | 108,029,516 | 105,063,437 | 105,063,437 |
| Issued and paid-up share capital | $ | $ 2,919,910 | $ 2,836,139 | ||
| NIS [Member] | ||||
| Number of Ordinary Shares | ||||
| Authorized share capital | ₪ | ₪ 25,000,000 | ₪ 25,000,000 | ||
| Issued and paid-up share capital | ₪ | ₪ 10,802,952 | ₪ 10,506,344 |
| REALIZATION OF INVESTMENT IN JOINT VENTURE (iPharma) (Details) - USD ($) $ in Thousands | 1 Months Ended | 6 Months Ended | ||
| Apr. 30, 2018 | Jun. 30, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
| Disclosure of joint ventures [line items] | ||||
| Initial seed capital to joint venture | $ 1,000 | |||
| I-Bridge Capital [Member] | ||||
| Disclosure of joint ventures [line items] | ||||
| Initial seed capital to joint venture | $ 1,000 | |||
| Cash consideration to joint venture | $ 1,500 | |||
| Net gain | $ 500 |
